ArticleCell reports2018
Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System.
Abstract read
In one paragraph
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Engineered tissues and strategies to overcome challenges in drug development.Advanced drug delivery reviews · 2020Pooled it
- Development of iPSC-derived T cells targeting EGFR neoantigens in non-small cell lung cancer.Molecular therapy. Methods & clinical development · 2025Article
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- Regenerative Immunotherapy for Cancer: Transcription Factor Reprogramming of Tumor-Specific T Cells.Cancers · 2025Review
- Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.Frontiers in cell and developmental biology · 2024Review
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
- The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.Biology · 2023Review
- Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells.Cancer research communications · 2023Article
- Re-generation of cytotoxic γδT cells with distinctive signatures from human γδT-derived iPSCs.Stem cell reports · 2023Article
- 'Off the shelf' immunotherapies: Generation and application of pluripotent stem cell-derived immune cells.Cell proliferation · 2023Review
- Neoantigens: promising targets for cancer therapy.Signal transduction and targeted therapy · 2023Review
- Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy.Frontiers in medicine · 2023Review
- EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.Cell stem cell · 2022Article
- Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells.Experimental hematology & oncology · 2022Review
- 3D-organoid culture supports differentiation of human CARCell stem cell · 2022Article
- Induction of γδT cells from HSC-enriched BMCs co-cultured with iPSC-derived thymic epithelial cells.Journal of cellular and molecular medicine · 2021Article
- Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches.Cancer discovery · 2021Review
- Article
- Thymus Degeneration and Regeneration.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Raul VizcardoSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: vizcardo@nih.gov.
Nicholas D KlemenSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
S M Rafiqul IslamSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Devikala GurusamySurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Naritaka TamaokiSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Daisuke YamadaLaboratory of Developmental Genetics, RIKEN Center for Integrative Medical Science, Yokohama, Kanagawa 230-0045, Japan.
Haruhiko KosekiLaboratory of Developmental Genetics, RIKEN Center for Integrative Medical Science, Yokohama, Kanagawa 230-0045, Japan.
Benjamin L KidderDepartment of Oncology and Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Zhiya YuSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Li JiaSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Amanda N HenningSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Meghan L GoodSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Marta Bosch-MarceSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Takuya MaedaSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Chengyu LiuTransgenic Core, Division of Intramural Research, National Heart, Lung and Blood Institute, NIH, Bethesda, MD 20892, USA.
Zied AbdullaevExperimental Pathology Laboratory, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Svetlana PackExperimental Pathology Laboratory, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Douglas C PalmerSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
David F StroncekDepartment of Transfusion Medicine Department, Clinical Center, NIH, Bethesda, MD 20892, USA.
Fumito ItoDepartment of Surgical Oncology, Roswell Park Cancer Center, Buffalo, NY 14263, USA; Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Francis A FlomerfeltExperimental Transplantation and Immunology Branch, NIH Clinical Center, NIH, Bethesda, MD 20892, USA.
Michael J KruhlakExperimental Immunology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Nicholas P RestifoSurgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Center for Cell-Based Therapy, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: restifo@nih.gov.
Funding
Transgenic CoreZICHL005907 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LIU, CHENGYU · 2010 to 2025
$25.8MBuilding on the success of the adoptive immunotherapy of cancerZ01BC010763 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RESTIFO, NICHOLAS P · 2006 to 2008
$6.4MEIB Microscopy Core FacilityZICBC010915 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WISNIEWSKI, JAN · 2009 to 2025
$6.1MAdoptive Cell Therapy with Rejuvenated Antigen-Specific T CellsK08CA197966 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ITO, FUMITO · 2015 to 2019
$875kMolecular Mechanisms of Cancer DevelopmentZICBC011842 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PACK, SVETLANA · 2018 to 2020
$458kIntramural NIH HHS Z01 BC010763NCI NIH HHS K08 CA197966
Abstract
Induced pluripotent stem cell (iPSC)-derived T cells may provide future therapies for cancer patients, but those generated by current methods, such as the OP9/DLL1 system, have shown abnormalities that pose major barriers for clinical translation. Our data indicate that these iPSC-derived CD8 single-positive T cells are more like CD4
Indexed as
Cell Culture TechniquesCell DifferentiationHumansImaging, Three-DimensionalInduced Pluripotent Stem CellsThymus Gland3D cultureadoptive cell transferfetal thymus organ cultureimmunotherapyiPSC differentiationnaïve T cellrecent rhymic emigrantsT cell differentiationthymopoiesistumor antigen specific T cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.